INS and Hypoglycemia: In trials comparing IDegAsp BID with BIAsp 30 highlighted the improved FPG-lowering ability of IDegAsp at comparable total insulin doses [25,26] and significantly lower risk of overall confirmed and nocturnal hypoglycemia [25,27].